Neurocrine Biosciences, Inc.

The momentum for this stock is not very good. Neurocrine Biosciences, Inc. has good growth characteristics. Neurocrine Biosciences, Inc. is not very popular among insiders. Neurocrine Biosciences, Inc. is a mediocre stock to choose.
Log in to see more information.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, d...
NBIX Fundamental Data by TradingView

News

Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

PR Newswire Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia Neurocrine Biosciences Provides Update on ERUDITE...\n more…

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $160.00 at Barclays
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $160.00 at Barclays

Zolmax Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) had its price target decreased by investment analysts at Barclays from $180.00 to $160.00 in a research report issued to clients and investors...\n more…

Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

PR Newswire Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference PR Newswire SAN DIEGO...\n more…

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Cut to $160.00
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Cut to $160.00

Ticker Report Neurocrine Biosciences (NASDAQ:NBIX - Free Report) had its price objective cut by Barclays from $180.00 to $160.00 in a report published on Monday, Benzinga reports. They currently have an overweight...\n more…

Los Angeles Capital Management LLC Has $7.83 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Los Angeles Capital Management LLC Has $7.83 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Ticker Report Los Angeles Capital Management LLC trimmed its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 76.8% in the second quarter, according to the company in its most recent Form...\n more…

TD Asset Management Inc Sells 3,167 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
TD Asset Management Inc Sells 3,167 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Ticker Report TD Asset Management Inc cut its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.2% during the 2nd quarter, Holdings Channel reports. The firm owned 140,267 shares...\n more…